A novel Venturi system to generate high flow with titratable FiO2

Coppadoro, Andrea; Bellani, Giacomo

doi:10.33393/ao.2021.2284

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As observed in our results, the specifically designed Venturi system significantly reduced oxygen consumption while allowing to reach and maintain FiO 2 above 50%. The oxygen flow drives into a larger conduit, generating a decrease of pressure that absorbs external air and creates a mixture of air-oxygen at a higher flow [ 19 ]. The Venturi system of Bag-CPAP was frugally designed to specifically meet the clinical needs observed in real life, i.e., to optimize oxygen consumption [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

A new reservoir-based CPAP with low oxygen consumption: the Bag-CPAP

et al. 2023

View full text Add to dashboard Cite

Background Several noninvasive ventilatory supports rely in their design on high oxygen consumption which may precipitate oxygen shortage, as experienced during the COVID-19 pandemic. In this bench-to-bedside study, we assessed the performance of a new continuous positive airway pressure (CPAP) device integrating a large reservoir (“Bag-CPAP”) designed to minimize oxygen consumption, and compared it with other CPAP devices. Methods First, a bench study compared the performances of Bag-CPAP and four CPAP devices with an intensive care unit ventilator. Two FiO2 targets (40–60% and 80–100%) at a predefined positive end expiratory pressure (PEEP) level between 5 and 10 cm H2O were tested and fraction of inspired oxygen (FiO2) and oxygen consumption were measured. Device-imposed work of breathing (WOB) was also evaluated. Second, an observational clinical study evaluated the new CPAP in 20 adult patients with acute respiratory failure in two hospitals in France. Actual FiO2, PEEP, peripheral oxygen saturation, respiratory rate, and dyspnea score were assessed. Results All six systems tested in the bench study reached the minimal FiO2 target of 40% and four reached at least 80% FiO2 while maintaining PEEP in the predefined range. Device-delivered FiO2/consumed oxygen ratio was the highest with the new reservoir-based CPAP irrespective of FiO2 target. WOB induced by the device was higher with Bag-CPAP. In the clinical study, Bag-CPAP was well tolerated and could reach high (> 90%) and moderate (> 50%) FiO2 with an oxygen flow rate of 15 [15–16] and 8 [7–9] L/min, respectively. Dyspnea score improved significantly after introduction of Bag-CPAP, and SpO2 increased. Conclusions In vitro, Bag-CPAP exhibited the highest oxygen saving properties albeit had increased WOB. It was well accepted clinically and reduced dyspnea. Bag-CPAP may be useful to treat patients with acute respiratory failure in the field, especially when facing constraints in oxygen delivery.

show abstract

Section: Discussionmentioning

confidence: 99%

A new reservoir-based CPAP with low oxygen consumption: the Bag-CPAP

et al. 2023

View full text Add to dashboard Cite

show abstract

A new reservoir-based CPAP with low oxygen consumption. The Bag-CPAP

Beaufort

Carteaux

Morin

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Several forms of noninvasive ventilatory supports have a high consumption of oxygen which may precipitate oxygen shortage, as experienced during the COVID-19 pandemic. In this bench-to-bedside study, we assessed the performances of a new continuous positive airway pressure (CPAP) device using a large a reservoir (the “Bag-CPAP”) designed to minimize oxygen consumption and compared it with other CPAP devices. Methods First, a bench study compared the performances of the Bag-CPAP and four CPAP devices to an intensive care unit ventilator. Two FiO2 targets (40-60% and 80-100%) at a predefined positive end expiratory pressure (PEEP) level between 5 and 10 cm H2O were tested and fraction of inspired oxygen (FiO2) and oxygen consumption were measured. Device-imposed work of breathing (WOB) was also evaluated. Second, an observational clinical study evaluated the new CPAP in 20 adult patients with acute respiratory failure in two hospitals in France. Actual FiO2, PEEP, peripheral oxygen saturation, respiratory rate and dyspnea score were assessed. Results All six systems tested in the bench study reached the minimal FiO2 target of 40% and four were able to reach at least 80% FiO2 while maintaining PEEP in the predefined range. The ratio of FiO2 delivered to the oxygen consumed was the highest with the new reservoir-based CPAP whatever the FiO2 target. The WOB induced by the device was slightly higher with the Bag-CPAP. In the clinical study, the Bag-CPAP was well tolerated and could reach high (>90%) and moderate (>50%) FiO2 with an oxygen flow rate of 15 [15-16] and 8 [7-9] L/min, respectively. Dyspnea score improved significantly after introduction of Bag-CPAP, and SpO2 increased. Conclusions In vitro, the Bag-CPAP exhibited the highest oxygen saving properties. It was well accepted clinically and reduces dyspnea. The Bag-CPAP may be useful to treat patients with acute respiratory failure in the field, especially when facing constraints in oxygen delivery.

show abstract

A novel Venturi system to generate high flow with titratable FiO2

Cited by 2 publications

References 8 publications

A new reservoir-based CPAP with low oxygen consumption: the Bag-CPAP

A new reservoir-based CPAP with low oxygen consumption: the Bag-CPAP

A new reservoir-based CPAP with low oxygen consumption. The Bag-CPAP

Contact Info

Product

Resources

About